🇺🇸 FDA
Company

Marker

Marker Therapeutics

MRKR pharma USA

Quick answer

Marker is a pharma company (MRKR) headquartered in HOUSTON, TX, USA with 13 tracked pipeline programs.

Pipeline (13)

project

FRα peptide plus Adjuvant (GM-CSF)

Platinum Sensitive Ovarian Cancer

Phase 2 · mab · terminated

1 trials project

Low dose FRα vaccine

Breast Cancer

Phase 2 · mab · completed

1 trials project

MT-401

Acute Myeloid Leukemia

Phase 2 · small_molecule · terminated

1 trials project

TPIV200

Ovarian Cancer

Phase 2 · mab · completed

1 trials project

HER-2/neu peptide vaccine

HER2-positive Breast Cancer

Phase 1 · mab · completed

1 trials project

MT-401-OTS

Acute Myeloid Leukemia, in Relapse

Phase 1 · small_molecule · active

1 trials project

MT-601

Non-Hodgkin Lymphoma, Adult

Phase 1 · small_molecule · active

1 trials project

MT-601 dose 200 million cells

Pancreas Cancer

Phase 1 · small_molecule · active

1 trials project

Mail-in Urine Test for EDCs

Endocrine Disrupting Chemicals

Unknown · other · completed

1 trials project

Urinary EDC metabolite testing

Obesity &Amp;Amp;Amp; Overweight

Unknown · other · active

1 trials project

Urinary EDC metabolite testing

Environmental Exposure

Unknown · other · active

1 trials project

blood sampling

Colorectal Cancer Screening

Unknown · other · completed

1 trials project

blood sampling

Screening for Colon Cancer

Unknown · other · active

1 trials

Patents (8)

patent

US 12077601

Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary ac

Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11885817

Biomarkers and methods for detection of seizures and epilepsy

Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11692030

Biomarkers and methods for detection of seizures and epilepsy

Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11598782

Biomarkers and methods for detection of seizures and epilepsy

Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11447500

Thienopyridine derivatives and pharmaceutical composition comprising same

Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11186873

Combination method for treating cancer by targeting immunoglobulin superfamily m

Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11078298

Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary ac

Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11008622

Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof

Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)